- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01471210
Safety, Tolerability, Pharmacokinetics, and Immunoregulatory Study of Urelumab (BMS-663513) in Subjects With Advanced and/or Metastatic Solid Tumors and Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma
A Phase 1 Study of the Safety, Tolerability, Pharmacokinetics and Immunoregulatory Activity of Urelumab (BMS-663513) in Subjects With Advanced and/or Metastatic Solid Tumors and Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma (B-NHL)
Study Overview
Status
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Creteil Cedex, France, 94010
- Local Institution
-
Lille Cedex, France, 59037
- Local Institution
-
Paris, France, 75475
- Local Institution
-
Pessac, France, 33604
- Local Institution
-
Pierre Benite Cedex, France, 69495
- Local Institution
-
Rennes Cedex 9, France, 35033
- Local Institution
-
Rouen, France, F-76038
- Local Institution
-
Villejuif Cedex, France, 94805
- Local Institution
-
-
-
-
-
Essen, Germany, 45147
- Local Institution
-
-
-
-
-
Barcelona, Spain, 08035
- Hospital Universitari Vall d'Hebron
-
Madrid, Spain, 28040
- Fundacion Jimenez Diaz
-
Pamplona, Spain, 31192
- Local Institution
-
-
-
-
California
-
Los Angeles, California, United States, 90095
- Division Of Hematology & Oncology Ctr. For Health Sciences
-
Stanford, California, United States, 94305
- Stanford University Medical Center
-
-
Illinois
-
Chicago, Illinois, United States, 60637
- University Of Chicago
-
-
Indiana
-
Indianapolis, Indiana, United States, 46202
- Indiana University Cancer Center
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02215
- Dana Farber Cancer Institute
-
-
Michigan
-
Detroit, Michigan, United States, 48201
- Karmanos Cancer Institute
-
-
New Jersey
-
Hackensack, New Jersey, United States, 07601
- John Theurer Cancer Center
-
-
New York
-
New York, New York, United States, 10065
- Memorial Sloan Kettering Cancer Center
-
-
Oregon
-
Portland, Oregon, United States, 97213
- Providence Portland Med Ctr
-
-
Pennsylvania
-
Hershey, Pennsylvania, United States, 17033
- Penn State Milton S. Hershey Medical Center
-
Philadelphia, Pennsylvania, United States, 19104
- Hospital of the University of Pennsylvania
-
-
Virginia
-
Charlottesville, Virginia, United States, 22908
- University Of Virginia Health System
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com.
Inclusion Criteria:
Signed Written Informed Consent
- The signed informed consent form
Target Population
- Subjects with advanced and/or metastatic solid tumors or B-NHL who are either refractory to or have relapsed from standard therapies, or for whom a standard therapy does not exist with measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria
- Life expectancy of 12 weeks or greater
- Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1
- Adequate organ and marrow function
- For certain subjects, willing and able to provide pre- and post-treatment fresh tumor biopsies
Age and Reproductive Status
- Women of childbearing potential (WOCBP) and men must be using an acceptable method of contraception to avoid pregnancy throughout the study and for at least 4 weeks prior to initiation of dosing, and for at least 60 days after the last dose of investigational product in such a manner that the risk of pregnancy is minimized
- WOCBP must have a negative serum or urine pregnancy test [minimum sensitivity 25 UI/L or equivalent units of human chorionic gonadotrophin (HCG)] within 24 hours prior to the start of investigational product
- Women must not be breastfeeding
Exclusion Criteria:
Target Disease Exceptions
- Subjects with known or suspected brain metastasis unless previously treated and without evidence of progression
- Subjects with a history of prior malignancy active within the previous 2 years except for locally curable cancers that have been apparently cured
- Subjects with hepatocellular carcinoma
Medical History and Concurrent Diseases
- Any active autoimmune disease or documented history of autoimmune disease, or history of syndrome that required systemic steroids or immunosuppressive medications, except for subjects with vitiligo, psoriasis inactive within past 2 years, resolved childhood asthma/atopy, or thyroid disease controlled by replacement therapy without the need for immunosuppression
- Known or suspected human immunodeficiency virus (HIV) or hepatitis A(acute), B or C infection
- History of any hepatitis (e.g., alcohol or non-alcohol steatohepatitis (NASH), drug-related, auto-immune)
- Evidence of active infection, requiring parenteral anti-bacterial, anti-viral or anti-fungal therapy < 7 days prior to administration of study medication
- History of clinically significant cardiac disease, including but not limited to a history (personal or family) of congenital long QT syndrome
- Grade > 1 QTc prolongation at baseline (> 450 msec by Bazett formula) confirmed by a repeat electrocardiogram (ECG)
- History of myocardial infarction or uncontrolled angina within 12 months prior to administration of study drug
Physical and Laboratory Test Findings
- WOCBP who are unwilling or unable to use an acceptable method to avoid pregnancy for the entire study period and for up to 12 weeks after the last dose of investigational product
- Women who are pregnant or breastfeeding
- Women with a positive pregnancy test on enrollment or prior to investigational product administration
- Sexually active fertile men not using effective birth control if their partners are WOCBP
- Positive blood screen for hepatitis A IgM, hepatitis C antibody, hepatitis B surface antigen, or HIV-1, -2 antibody
Allergies and Adverse Drug Reaction
- History of allergy to Urelumab (BMS-663513) or related compounds
- History of significant drug allergy (such as anaphylaxis or hepatotoxicity) to a prior biologic therapy
Prohibited Treatments and/or Therapies
The systemic use of the following therapies are prohibited within 28 days of first dose of study medication, or longer where indicated:
- Use of anti-cancer treatment (including investigational drugs) within 28 days
- Immunosuppressive medications or immunosuppressive doses of systemic corticosteroids
- Surgery (except minor surgeries,e.g., biopsies) or radiotherapy
- Any non-oncology live viral vaccine therapies used for the prevention of infectious diseases.
- Prior treatment with anti-programmed death 1 (anti-PD-1)/Programmed cell death 1 ligand 1 (PD-L1) or anti-CD137
- Any subject with the following reported drug-related adverse events on anti- Cytotoxic T-Lymphocyte Antigen 4 (anti-CTLA4) will not be permitted on study: hepatic, diarrhea/colitis or endocrine adverse events (AE)s Grade ≥ 2, any other non-laboratory immune-related AE ≥ Grade 3. Subjects must have minimum 9 week washout period between the last dose of anti-CTLA4 and the first dose Urelumab (BMS-663513)
- Prior organ allograft or allogeneic bone marrow transplantation
Other Exclusion Criteria
- Prisoners or subjects who are involuntarily incarcerated
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NON_RANDOMIZED
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Part 1 : Urelumab (BMS-663513) Dose escalation
Urelumab (BMS-663513) solution administered intravenously on specified days
|
|
EXPERIMENTAL: Part 2 : Urelumab (BMS-663513) Cohort Expansion
Urelumab (BMS-663513) solution administered intravenously on specified days
|
|
EXPERIMENTAL: Part 3:Urelumab (BMS-663513) Tumor-specific Cohort Expansions
Enrollment of subjects of three specific tumor types [(colorectal cancer (CRC), head and neck squamous cell carcinoma (SCCHN), and B-Cell non-Hodgkin's lymphoma (B-NHL)] who will be treated at the Maximum Tolerated Dose (MTD) (or highest dose tested)
|
|
EXPERIMENTAL: Part 4:Urelumab (BMS-663513) Cohort Expansion in B-NHL
Arm A and Arm B: Urelumab (BMS-663513) liquid administered intravenously on specified days exploring q3w and q6w dosing regimen
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety assessments will be based on medical review of adverse event reports and the results of vital sign measurements, physical examinations, and clinical laboratory tests
Time Frame: Every 3 weeks from Baseline (Day 1) for up to 2 years
|
The incidence of adverse events will be tabulated and reviewed for potential significance and clinical Importance.
|
Every 3 weeks from Baseline (Day 1) for up to 2 years
|
Dose-limiting toxicity and maximum tolerated dose of Urelumab (BMS-663513) as determined by the incidence of dose-limiting toxicities
Time Frame: Every 3 weeks from Baseline (Day 1) for up to 9 weeks of therapy
|
Every 3 weeks from Baseline (Day 1) for up to 9 weeks of therapy
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Maximum observed serum concentrations (Cmax) of Urelumab (BMS-663513)
Time Frame: Cycle 1 Day 1
|
Cycle 1 Day 1
|
|
Minimum observed serum concentrations (Cmin) of Urelumab (BMS-663513)
Time Frame: Cycle 2 Day 1, Cycle 3 Day 1, every 12 weeks thereafter up to 2 years
|
Cycle 2 Day 1, Cycle 3 Day 1, every 12 weeks thereafter up to 2 years
|
|
Time of maximum observed serum concentration (Tmax) of Urelumab (BMS-663513)
Time Frame: Cycle 1 Day 1
|
Cycle 1 Day 1
|
|
Area under the concentration-time curve in 1 dosing interval [AUC(TAU)] of Urelumab (BMS-663513)
Time Frame: Cycle 1 Day 1 - Day 4, Cycle 1 Day 8, Cycle 1 Day 15, Cycle 2 Day 1, Cycle 2 Day 8, Cycle 3 Day 1 and every 12 weeks thereafter up to 2 years
|
Cycle 1 Day 1 - Day 4, Cycle 1 Day 8, Cycle 1 Day 15, Cycle 2 Day 1, Cycle 2 Day 8, Cycle 3 Day 1 and every 12 weeks thereafter up to 2 years
|
|
Plasma half-life (T-HALF) of Urelumab (BMS-663513)
Time Frame: Cycle 1 Day 1 - Day 4, Cycle 1 Day 8, Cycle 1 Day 15, Cycle 2 Day 1, Cycle 2 Day 8, Cycle 3 Day 1 and every 12 weeks thereafter up to 2 years
|
Cycle 1 Day 1 - Day 4, Cycle 1 Day 8, Cycle 1 Day 15, Cycle 2 Day 1, Cycle 2 Day 8, Cycle 3 Day 1 and every 12 weeks thereafter up to 2 years
|
|
Total body clearance (CLT) of Urelumab (BMS-663513)
Time Frame: Cycle 1 Day 1 - Day 4, Cycle 1 Day 8, Cycle 1 Day 15, Cycle 2 Day 1, Cycle 2 Day 8, Cycle 3 Day 1 and every 12 weeks thereafter up to 2 years
|
Cycle 1 Day 1 - Day 4, Cycle 1 Day 8, Cycle 1 Day 15, Cycle 2 Day 1, Cycle 2 Day 8, Cycle 3 Day 1 and every 12 weeks thereafter up to 2 years
|
|
Volume of distribution at steady-state (Vss) of Urelumab (BMS-663513)
Time Frame: Cycle 1 Day 1 - Day 4, Cycle 1 Day 8, Cycle 1 Day 15, Cycle 2 Day 1, Cycle 2 Day 8, Cycle 3 Day 1 and every 12 weeks thereafter up to 2 years
|
Cycle 1 Day 1 - Day 4, Cycle 1 Day 8, Cycle 1 Day 15, Cycle 2 Day 1, Cycle 2 Day 8, Cycle 3 Day 1 and every 12 weeks thereafter up to 2 years
|
|
Human Anti-human Antibodies
Time Frame: Cycle 1 Day 1 - Day 4, Cycle 1 Day 8, Cycle 1 Day 15, Cycle 2 Day 1, Cycle 2 Day 8, Cycle 3 Day 1 and every 12 weeks thereafter up to 2 years
|
Immunogenicity of Urelumab (BMS-663513), as determined by blood sample measurements of human antihuman antibodies (HAHA)
|
Cycle 1 Day 1 - Day 4, Cycle 1 Day 8, Cycle 1 Day 15, Cycle 2 Day 1, Cycle 2 Day 8, Cycle 3 Day 1 and every 12 weeks thereafter up to 2 years
|
Tumor response and progression as determined by proportion of patients with best overall response (BOR), progression-free survival (PFS), objective response rate (ORR), time to response, and duration of response
Time Frame: 9 weeks from Baseline (Day 1) and every 9 weeks until disease progression, death or last tumor assessment (Approximately up to 2 years)
|
9 weeks from Baseline (Day 1) and every 9 weeks until disease progression, death or last tumor assessment (Approximately up to 2 years)
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CA186-011
- 2012-000170-28 (EUDRACT_NUMBER)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cancer - Solid Tumors and B-Cell Non-Hodgkin's Lymphoma
-
Bristol-Myers SquibbTerminatedAdvanced Solid Tumors | Advanced B-cell NHLUnited States, France, Spain, Germany
-
Estrella Biopharma, Inc.Eureka Therapeutics Inc.Not yet recruitingLymphoma | Lymphoma, Non-Hodgkin | Non-Hodgkin's Lymphoma | Non-Hodgkin Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Refractory Non-Hodgkin Lymphoma | High-grade B-cell Lymphoma | CNS Lymphoma | Lymphomas Non-Hodgkin's B-Cell | Relapsed Non-Hodgkin Lymphoma | Lymphoma, Non-Hodgkins | Large B-Cell Lymphoma and other conditions
-
Antengene Biologics LimitedRecruitingAdvanced Solid Tumor | Metastatic Solid Tumor | Mature B-cell Non-Hodgkin LymphomaUnited States, Australia
-
City of Hope Medical CenterNational Cancer Institute (NCI)RecruitingRefractory B-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | High Grade B-Cell Non-Hodgkin's Lymphoma | Intermediate Grade B-Cell Non-Hodgkin's LymphomaUnited States
-
Hoffmann-La RocheCompletedDiffuse Large B-Cell Lymphoma, Non-Hodgkin's LymphomaHong Kong, Germany, Philippines, Taiwan, Turkey, Canada, Australia, Austria, New Zealand, Thailand, Hungary, Italy, Korea, Republic of, Romania, Netherlands, Brazil, Indonesia, Croatia, Egypt, Portugal, Sweden, Colombia, Argentina, De... and more
-
Caribou Biosciences, Inc.RecruitingLymphoma | Lymphoma, Non-Hodgkin | B Cell Lymphoma | Non Hodgkin Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Relapsed Non Hodgkin Lymphoma | B Cell Non-Hodgkin's LymphomaUnited States, Australia, Israel
-
Debiopharm International SACompletedDiffuse Large B-Cell Lymphoma | B-cell Non-Hodgkin's LymphomaUnited States, Czechia, Belgium, Hungary, Ukraine, Bulgaria, Italy, Poland, Switzerland
-
Eden BioCell Ltd.National Taiwan University HospitalTerminatedFollicular Lymphoma | Mantle Cell Lymphoma | Diffuse Large B Cell Lymphoma | B-cell Acute Lymphoblastic Leukemia | High-grade B-cell Lymphoma | Primary Mediastinal Large B Cell Lymphoma | Non-Hodgkin's Lymphoma, Relapsed | Non-Hodgkin's Lymphoma RefractoryTaiwan
-
Peking UniversityPeking University Cancer Hospital & InstituteRecruitingB Cell Non-Hodgkin's LymphomaChina
-
Peking UniversityUnknownB-cell Non-Hodgkin's Lymphoma
Clinical Trials on Urelumab (BMS-663513)
-
Bristol-Myers SquibbCompleted
-
Bristol-Myers SquibbCompletedHead and Neck Cancer | Colorectal CancerUnited States
-
Bristol-Myers SquibbTerminatedAdvanced Solid Tumors | Advanced B-cell NHLUnited States, France, Spain, Germany
-
Bristol-Myers SquibbCompletedB-Cell MalignanciesUnited States
-
University of ChicagoBristol-Myers SquibbCompletedCancerUnited States
-
Bristol-Myers SquibbTerminatedNon Small Cell Lung CancerUnited States
-
Bristol-Myers SquibbTerminated
-
Bristol-Myers SquibbTerminatedAdvanced Solid MalignanciesUnited States, Canada
-
Bristol-Myers SquibbCompletedMelanomaFrance, Italy, United States, Germany, Canada, Denmark
-
Sidney Kimmel Comprehensive Cancer Center at Johns...Bristol-Myers Squibb; National Cancer Institute (NCI)RecruitingPancreatic CancerUnited States